Stem (STEM)
(Delayed Data from NYSE)
$1.13 USD
-0.04 (-3.42%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $1.14 +0.01 (0.88%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Brokerage Reports
Stem, Inc. [STEM]
Reports for Purchase
Showing records 21 - 40 ( 81 total )
Company: Stem, Inc.
Industry: Unclassified
Company: Stem, Inc.
Industry: Unclassified
Encouraging Q4 Services Growth, but Lower-Than-Expected 2023 Guide
Provider: Roth Capital Partners, Inc.
Analyst: CLARE J
Company: Stem, Inc.
Industry: Unclassified
The Solar Snapshot - FSLR/Ute Module Pricing, ENPH, US Resi, EU Updates
Provider: Roth Capital Partners, Inc.
Analyst: SHEN P
Company: Stem, Inc.
Industry: Unclassified
Alternative Energy 2023 Sector Outlook: Cleared for Takeoff
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stem, Inc.
Industry: Unclassified
Alternative Energy Weekly (Clean Hydrogen Rule Making, AD/CVD, Solar Installation Trends, SMR, FCEL, Holtec, GE Hitachi)
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stem, Inc.
Industry: Unclassified
Company: Stem, Inc.
Industry: Unclassified
Impressive Growth, Looking for Software to Become the Key Revenue Driver -Initiation of Coverage
Provider: Roth Capital Partners, Inc.
Analyst: CLARE J
Company: Stem, Inc.
Industry: Unclassified
Company: Stem, Inc.
Industry: Unclassified
Utilities 3Q22 Earnings Preview: The Average Is Over: Staying Selective and Focusing on Catalysts Given Macro Headwinds
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stem, Inc.
Industry: Unclassified
Utilities 3Q22 Earnings Preview: The Average Is Over: Staying Selective and Focusing on Catalysts Given Macro Headwinds
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stem, Inc.
Industry: Unclassified
Utilities 2Q22 Earnings Preview: Peak Recession Fear
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stem, Inc.
Industry: Unclassified
Company: Stem, Inc.
Industry: Unclassified
Company: Stem, Inc.
Industry: Unclassified
Renewables 2022 Sector Outlook: Another Tough Year Ahead
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Stem, Inc.
Industry: Unclassified
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Study Terminated; Operations Winding Down; Terminating Coverage
Provider: Rodman & Renshaw, Co.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Study Terminated; Operations Winding Down; Terminating Coverage
Provider: H.C. Wainwright & Co., Inc.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Reverse Stock Split Effected; Reiterate Buy with Adjusted $18 Price Target
Provider: Rodman & Renshaw, Co.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Reverse Stock Split Effected; Reiterate Buy with Adjusted $18 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage With a Buy
Provider: H.C. Wainwright & Co., Inc.